Full-Time

Sr. Scientist

Discovery DMPK

Updated on 6/12/2025

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

501-1,000 employees

Develops RNAi-based therapies for diseases

Compensation Overview

$100k - $130k/yr

Senior, Expert

Madison, WI, USA

All applicants must have authorization to work in the US for a company.

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD in pharmacology or biological sciences
  • Hands-on experience with one of the quantitation method listed above from biological matrices
  • Hands-on experience with cell separation, enrichment or depletion
  • Demonstrated innovation, creativity and resilience in problem solving
  • Excellent oral and written communication skills and collaborative personality
  • Highly self-motivated with a can-do attitude
Responsibilities
  • Draft ADME study requests
  • Perform cell type separation, enrichment and depletion as needed
  • Perform LC-HRMS, LC-UV or qPCR based quantitation
  • Interpret ADME results to facilitate drug delivery
  • Act as discovery DMPK lead and present data in cross-functional meetings
  • Document experimental procedure and results accurately
  • Execute all assays in a timely manner to meet deadlines
  • Be able to work in a highly dynamic and fast-moving environment; meet project goal within deadline
Desired Qualifications
  • Extensive experience in cell separation, enrichment and depletion
  • Demonstrated practical understanding of pharmacokinetics and pharmacodynamics
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

View

Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing specific genes. The company uses RNA interference (RNAi), a natural process that reduces gene expression, to create therapies that can potentially stop or reverse diseases like cystic fibrosis and hepatitis B. Their approach involves a variety of RNA chemistries and effective delivery methods to ensure that the target genes are significantly reduced. Unlike many competitors, Arrowhead focuses specifically on RNAi-based therapies, which allows them to address medical needs that are not met by existing treatments. Their goal is to provide new options for patients suffering from genetic disorders and to advance the field of gene silencing therapies.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Pasadena, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Arrowhead's collaboration with Sarepta includes a $500M upfront payment for RNA drug development.
  • Positive Phase 2 data for plozasiran boosts Arrowhead's credibility in treating hypertriglyceridemia.
  • Strategic financing with Sixth Street provides capital to advance Arrowhead's research pipeline.

What critics are saying

  • Increased competition from companies like Alnylam may impact Arrowhead's market share.
  • Potential regulatory scrutiny could delay Arrowhead's clinical trials for RNAi therapies.
  • Reliance on strategic financing may lead to increased debt obligations for Arrowhead.

What makes Arrowhead Pharmaceuticals unique

  • Arrowhead uses RNAi to target and silence disease-causing genes effectively.
  • The company has a broad portfolio of RNA chemistries for diverse therapeutic applications.
  • Arrowhead's strategic partnerships enhance its capabilities in developing innovative RNAi therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Company News

BioSpace
Apr 15th, 2025
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Mr. Apel joins the company from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis from 2019 through 2024.

PharmaData
Mar 1st, 2025
Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day

Arrowhead Pharmaceuticals launches FCS patient resources on Rare Disease Day.

Business Wire
Feb 28th, 2025
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

New Patient Resource Hub: Arrowhead expands its We'll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides

World Pharmaceuticals
Nov 29th, 2024
Dev4All and Pharmaseed enter commercial partnership for preclinical R&D

Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes.

BioSpace
Nov 26th, 2024
Sarepta Aims Up to $10B at Arrowhead to Diversify Pipeline With RNA Drugs

Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of the muscle, central nervous system and lung.